Analytical Data
-
Gene name
Ptger4
- Application
-
Alternative Names
(PGE receptor EP4 subtype)(PGE2 receptor EP4 subtype)(Prostanoid EP4 receptor)
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P32240
-
Expression Region
361-513aa
-
Molecular Weight
16.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of Ptger4 recombinant protein primarily revolves around its role as a receptor for prostaglandin E2 (PGE2), which is a significant lipid compound involved in various physiological processes, including inflammation, immune response, and tissue homeostasis. Ptger4, also known as the prostaglandin E receptor 4, is part of the E series of prostaglandin receptors and exhibits a unique expression pattern in different tissues, contributing to diverse biological functions. Research has shown that Ptger4 mediates the actions of PGE2 in several contexts, including pain modulation, reproductive functions, and cardiovascular health. Given the receptor’s involvement in pathophysiological conditions such as cancer, cardiovascular diseases, and chronic inflammatory diseases, it has garnered attention as a potential therapeutic target. The generation of Ptger4 recombinant protein enables researchers to conduct detailed studies on its signaling mechanisms, ligand specificity, and therapeutic implications. By exploring the structure and function of this receptor, scientists aim to develop novel drug strategies that can modulate its activity, ultimately leading to improved treatments for diseases associated with aberrant PGE2 signaling. Understanding the biological roles and therapeutic potential of Ptger4 can pave the way for innovative approaches in personalized medicine, particularly in managing diseases characterized by inflammation and immune dysregulation. Additionally, the recombinant protein can serve as a valuable tool for elucidating further molecular pathways and interactions that govern the receptor's functions, thereby enhancing our overall understanding of prostaglandin biology in health and disease.
